G
Gary Bridger
Researcher at Johnson Matthey
Publications - 78
Citations - 8014
Gary Bridger is an academic researcher from Johnson Matthey. The author has contributed to research in topics: CD34 & Chemokine receptor. The author has an hindex of 37, co-authored 78 publications receiving 7730 citations. Previous affiliations of Gary Bridger include German Cancer Research Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
Hal E. Broxmeyer,Christie M. Orschell,D. Wade Clapp,Giao Hangoc,Scott Cooper,P. Artur Plett,W. Conrad Liles,Xiaxin Li,Barbara Graham-Evans,Timothy B. Campbell,Gary Calandra,Gary Bridger,David C. Dale,Edward F. Srour +13 more
TL;DR: Results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.
Journal ArticleDOI
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
W. Conrad Liles,W. Conrad Liles,Hal E. Broxmeyer,Hal E. Broxmeyer,Elin Rodger,Elin Rodger,Brent L. Wood,Brent L. Wood,Kai Hübel,Kai Hübel,Scott Cooper,Scott Cooper,Giao Hangoc,Giao Hangoc,Gary Bridger,Gary Bridger,Geoffrey W. Henson,Geoffrey W. Henson,Gary Calandra,Gary Calandra,David C. Dale +20 more
TL;DR: Findings suggest potential clinical application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation.
Journal ArticleDOI
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
John F. DiPersio,Ivana N. Micallef,Patrick J. Stiff,Brian J. Bolwell,Richard T. Maziarz,Eric D. Jacobsen,Auayporn Nademanee,John M. McCarty,Gary Bridger,Gary Calandra +9 more
TL;DR: Plerixafor and G- CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Journal ArticleDOI
Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers
Craig W. Hendrix,Charles Flexner,Ronald Trevor Macfarland,Christen Giandomenico,Edward J. Fuchs,Ella Redpath,Gary Bridger,Geoffrey W. Henson +7 more
TL;DR: ABSTRACT AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells via selective blockade of the chemokine CXCR-4 receptor.
Journal Article
Multiple Actions of the Chemokine CXCL12 on Epithelial Tumor Cells in Human Ovarian Cancer
Chris J. Scotton,Julia L. Wilson,Kate M. Scott,Gordon Stamp,George D. Wilbanks,Simon P. Fricker,Gary Bridger,Frances R. Balkwill +7 more
TL;DR: The chemokine CXCL12 may have multiple biological effects in ovarian cancer, stimulating cell migration and invasion through extracellular matrix, as well as DNA synthesis and establishment of a cytokine network in situations that are suboptimal for tumor cell growth.